How much does a box of Alpelisib-Piqray cost in 2023?

Alpelisib (Piqray) - Piqray is used to treat breast cancer in men and postmenopausal women that is HR-positive, HER2-negative, advanced or has spread to other parts of the body (metastatic). Apelvis is a targeted therapy drug from a class of drugs called PI3K inhibitors (phosphoinositide 3-kinase inhibitors), sometimes called kinase inhibitors. In May 2019, it became a drug approved by the U.S. Food and Drug Administration (FDA) as the first PI3K inhibitor targeting specific breast cancer.

Apelix is only used in breast cancer, and doctors will test patients if it has a specific PIK3CA mutation (an abnormal "PIK3CA" gene). Apelvis is combined with fulvestrant (Faslodex). Apelvis works by blocking PIK3CA and is therefore used to treat breast cancers with specific mutations in the PIK3CA gene. In breast cancer, mutations in the PIK3CA gene lead to tumor development, and Apelvis works to block PI3K, thereby reducing the growth of breast cancer. The combination of apelvis and fulvestrant had enhanced antitumor activity compared with either treatment alone.

The original drug of Apellis is not marketed in the country and therefore cannot be included in medical insurance. There are European and Indian versions of the original Apelvis drug sold overseas. The ingredients are basically the same. The price of the European version of 150mg*56 tablets per box may be more than 4 RMB 40,000 ( (The price may fluctuate due to the exchange rate), The price of the Indian version150mg*28 tablets per box may be more than 5,000 yuan (the price may fluctuate due to the exchange rate). There are currently no generic versions of Apelvis produced and marketed.